TRAJAN GROUP HOLDINGS LIMITED (TRJ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TRJ

TRJ - TRAJAN GROUP HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 4.47
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.165

27 Aug
2026

-0.015

OPEN

$0.18

-8.33%

HIGH

$0.19

1,085,560

LOW

$0.17

TARGET
$0.55 233.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
TRJ: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 0.4 3.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 5.4 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx161.4 M
Book Value Per Share xxxxxxxxxxxxxxx64.4
Net Operating Cash Flow xxxxxxxxxxxxxxx0.2 M
Net Profit Margin xxxxxxxxxxxxxxx-0.39 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-0.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-0.41 %
Return on Assets xxxxxxxxxxxxxxx-0.33 %
Return on Equity xxxxxxxxxxxxxxx-0.61 %
Return on Total Capital xxxxxxxxxxxxxxx2.67 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-3.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx8 M
Long Term Debt xxxxxxxxxxxxxxx50 M
Total Debt xxxxxxxxxxxxxxx58 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx13 M
Price To Book Value xxxxxxxxxxxxxxx0.31

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx3.4 M
Capex % of Sales xxxxxxxxxxxxxxx2.12 %
Cost of Goods Sold xxxxxxxxxxxxxxx145 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

28/08/2026

1

Hold

$0.50

203.03%

Bell Potter cuts its target for Trajan Group by -25c to $0.50 after FY26 results and retains its Buy rating.

FY26 normalised earnings (EBITDA) of $13.2m were around -6% below the broker's forecast, reflecting foreign exchange impacts.

Commentary notes performance improved materially in the second half, with earnings rising 61% half-on-half as cost reductions and margins improved.

FY27 guidance implies mid-single-digit revenue growth and double-digit earnings growth to Bell Potter.

FY27-FY29 earnings forecasts fall by -10%, -14% and -21%, respectively, reflecting weaker revenue assumptions and ongoing macroeconomic volatility, the analysts explain.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.80 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 4.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

TRJ STOCK CHART

FNArena News on TRJ

1
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia
2
FNArena Corporate Results Monitor – 27-02-2026

Feb 27 2026 - Australia
3
Australian Broker Call *Extra* Edition – Sep 04, 2025

Sep 04 2025 - Daily Market Reports
4
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
5
Australian Broker Call *Extra* Edition – Aug 08, 2025

Aug 11 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals